ANGPT2 and neoplasm: (3) Targeting tumour vasculature associated signalling pathways, including blockade of VEGF-A and ANG2 reinforced the antigen-presenting ability of DCs, and the combined therapy potentiated DCs to present an activated phenotype characterised by increased expression of MHC-II and CD86 [201].